Table 1.
Characteristics of Subjects Enrolled in the Ancillary Study
| 17-OHPC (N=99) | Placebo (N=118) | P value | |
|---|---|---|---|
|
| |||
| Maternal age (years) | 29 (26–35) | 30 (24–35) | 0.96 |
| Nulliparous | 40 (40.4%) | 55 (46.6%) | 0.36 |
| Prior preterm birth | 9 (9.0%) | 8 (6.8%) | 0.53 |
| Race/ethnicity | 0.91 | ||
| African American | 24 (24.2%) | 27 (22.9%) | |
| Hispanic | 14 (14.1%) | 15 (12.7%) | |
| Caucasian/other | 61 (61.6%) | 76 (64.4%) | |
| BMI at enrollment | 26.7 (22.5–30.5) | 24.3 (21.0–28.7) | 0.07 |
| Gestational age at enrollment (weeks) | 19 (18–20) | 19 (18–20) | 0.75 |
| Gestational age at delivery (weeks) | 35.9 (34.1–37.1) | 36 (34.1–37.3) | 00.76 |
| Delivery < 37 weeks | 67(67.7%) | 84(71.2%) | 0.58 |
| Delivery < 34 weeks | 24(24.2%) | 25 (21.2%) | 0.59 |
| Monochorionic | 14 (14.1%) | 18 (15.3%) | 0.82 |
| Gestational age at 1st blood draw (weeks) | 26.3 (25.4–27.1) | 26.3 (25.6–27.0) | 0.84 |
| Number of injections by 1st blood draw | 7 (6–8) | 7 (6–8) | 0.58 |
| Gestational age at 2nd blood draw (weeks)* | 32.7(32.3–33.6) | 33.3 (32.7 – 33.9) | 0.02 |
| Number of injections by 2nd blood draw* | 14 (12–15) | 14 (13–15) | 0.82 |
Values expressed as n (%) or median and interquartile range. P-values are from Chi-square or Wilcoxon tests as appropriate
*
Based on 72 women in the 17OHPC group and 92 women in the placebo group who completed all of their injections through the second blood draw